148 filings
Page 3 of 8
424B3
y4henl
11 May 23
Prospectus supplement
4:37pm
8-K
t7a95ddk4wks
11 May 23
Akili Reports First Quarter 2023 Financial Results and Provides Business Update
4:26pm
424B3
omw9b 0ifc6vp
4 May 23
Prospectus supplement
4:08pm
8-K
vx09302
4 May 23
Submission of Matters to a Vote of Security Holders
4:06pm
424B3
tj9v2
3 May 23
Prospectus supplement
4:11pm
8-K
qdt8ccy
3 May 23
Regulation FD Disclosure
4:07pm
EFFECT
8ubf0
27 Mar 23
Notice of effectiveness
12:15am
ARS
7tcbjn7phz pm7narrp
22 Mar 23
Annual report to shareholders
4:22pm
DEFA14A
0nmx 1wck
22 Mar 23
Additional proxy soliciting materials
4:18pm
DEF 14A
ucfu n3qwnbir
22 Mar 23
Definitive proxy
4:16pm
POS AM
92zc2tppx
21 Mar 23
Prospectus update (post-effective amendment)
4:07pm
424B3
yv87 kppnapezdemet2
7 Mar 23
Prospectus supplement
4:25pm
8-K
ynpig4u
7 Mar 23
Akili Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
4:13pm
424B3
1g6kt
12 Jan 23
Prospectus supplement
8:13am
8-K
q61etq0xm 1o
12 Jan 23
Cost Associated with Exit or Disposal Activities
8:06am
424B3
coi 5rkrxory6
5 Jan 23
Prospectus supplement
7:21am
8-K
st01a6 udgss
5 Jan 23
Pivotal Trial of EndeavorRx® in Adolescents with ADHD Shows Robust Improvements in Attention and Broader Clinical Outcomes
7:14am
8-K/A
wmzlziu3 pju
27 Dec 22
Entry into a Material Definitive Agreement
9:19am
8-K
949drdt5 swv17e
23 Dec 22
Entry into a Material Definitive Agreement
4:12pm